|
Market Closed -
NYSE
05:00:00 17/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 3.030 USD | -0.66% |
|
+17.90% | +68.33% |
| 11-11 | Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2026 | CI |
| 11-10 | Protalix BioTherapeutics, Inc., Q3 2026 Earnings Call, Nov 10, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PROTALIX BIOTHERAPEUTICS, INC. | Other Pharmaceuticals | -0.66% | +17.90% | +68.33% | +60.32% | +175.45% | 257M |
- Stock Market
- Stocks
- PLX Stock
- Charts Protalix BioTherapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
















